NYSE$MD
Pediatrix Medical Group, Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported earnings from continuing operations and announced multi-state, unilateral termination by UnitedHealth Group.
MEDNAX reported Q4 2019 results with net revenue of $905 million and earnings from continuing operations of $0.40 per share. Adjusted EPS from continuing operations was $0.91. The company also announced a unilateral, multi-state termination by UnitedHealth Group.
- Net revenue for the fourth quarter was $905 million.
- Net income for the fourth quarter was $33 million.
- Adjusted EBITDA for the fourth quarter was $132 million.
- Adjusted EPS from continuing operations was $0.91.
Headline financials
Revenue & EPS history
Pediatrix · Revenue · Quarterly
$905M
Forward guidance
For the first quarter of 2020, MEDNAX expects Adjusted EPS to be in the range of $0.55 to $0.63 and Adjusted EBITDA to be $95 million at the midpoint, with a range of between $90 million and $100 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
34 / 68 earnings
Positive
+31.3%
Q3 2020
Best reaction
-24.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.3% | +5.2% | +0.0% | |
| Q4 2025 | -12.2% | -8.7% | -10.3% | |
| Q3 2025 | +21.3% | +29.2% | +37.2% | |
| Q1 2025 | +12.1% | +12.2% | +7.5% | |
| Q4 2024 | +22.1% | +9.1% | +0.7% | |
| Q3 2024 | +22.9% | +30.5% | +21.4% | |
| Q2 2024 | +26.4% | +31.5% | +40.9% | |
| Q1 2024 | -8.4% | -11.4% | -25.8% | |
| Q4 2023 | -6.8% | -5.4% | +0.6% | |
| Q3 2023 | -11.7% | -11.8% | -21.8% | |
| Q2 2023 | +5.9% | +6.4% | +1.2% | |
| Q1 2023 | -2.4% | -4.5% | -5.4% | |
| Q4 2022 | +4.6% | +5.8% | -5.0% | |
| Q3 2022 | -16.2% | -18.3% | -12.6% | |
| Q2 2022 | -12.1% | -7.8% | -22.1% | |
| Q1 2022 | -18.5% | -16.6% | -14.4% | |
| Q4 2021 | -9.2% | -8.9% | -6.9% | |
| Q3 2021 | -1.2% | -3.3% | -10.7% | |
| Q2 2021 | +7.9% | +11.4% | +2.1% | |
| Q1 2021 | +19.5% | +14.8% | +19.4% | |
| Q4 2020 | -20.5% | -16.8% | -0.9% | |
| Q3 2020 | +31.3% | +32.0% | +60.5% | |
| Q2 2020 | -1.3% | -1.3% | -4.6% | |
| Q1 2020 | +5.6% | -0.7% | +38.7% | |
| Q4 2019 | -24.8% | -30.0% | -64.6% | |
| Q3 2019 | +14.6% | +18.1% | +18.9% | |
| Q2 2019 | -9.1% | -13.6% | -14.2% | |
| Q1 2019 | +3.8% | +3.8% | -12.7% | |
| Q4 2018 | -4.2% | -5.9% | -18.3% | |
| Q3 2018 | -5.0% | -4.4% | -2.6% | |
| Q2 2018 | +10.1% | +13.3% | +10.4% | |
| Q1 2018 | -4.4% | -3.6% | -1.4% | |
| Q4 2017 | +6.6% | +6.7% | +13.8% | |
| Q3 2017 | -4.9% | +0.1% | +15.6% | |
| Q2 2017 | -16.8% | -20.4% | -21.7% | |
| Q1 2017 | -8.5% | -9.9% | -8.2% | |
| Q4 2016 | -3.5% | -1.3% | +1.1% | |
| Q3 2016 | -6.3% | -6.3% | +1.3% | |
| Q2 2016 | -8.5% | -10.8% | -16.7% | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | +4.2% | — | — | |
| Q1 2015 | -1.2% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | +10.2% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q4 2013 | +5.0% | — | — | |
| Q3 2013 | +2.4% | — | — | |
| Q2 2013 | +1.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +7.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | -6.6% | — | — | |
| Q4 2011 | -1.7% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -0.9% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2011 | +4.5% | — | — | |
| Q4 2010 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — | |
| Q3 2009 | +2.0% | — | — | |
| Q3 2010 | +2.0% | — | — | |
| Q2 2010 | +2.3% | — | — | |
| Q4 2009 | +2.3% | — | — | |
| Q2 2009 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro